Cindy McEvoy, M.D. talks about a recent survey suggesting that some women believe that, during pregnancy, e-cigarette use is safer than smoking.

Jonah Sacha, Ph.D. comments on a new Nature study that outlines the case of a London-based HIV patient who has achieved long-term remission following stem cell transplant.

A patient utilizes OHSU’s virtual urgent care service to rule-out the possibility of measles.

In response to the Food and Drug Administration’s approval of ketamine for treatment of depression, Erik Turner, M.D. says, “Thank goodness we now have something with a different mechanism of action than previous antidepressants. But I’m skeptical of the hype, because in this world it’s like Lucy holding the football for Charlie Brown: Each time we get our hopes up, the football gets pulled away.”

Dublin-based drug development company ICON acquires OHSU spin-off MolecularMD, founded by Brian Druker, M.D., and Michael Heinrich, M.D.

A second round of the OHSU-UO Collaborative Seed Grant funding program is announced, which develops and builds new collaborations between researchers at OHSU and the University of Oregon.

Research conducted at the Oregon National Primate Research Center determines that mosaic embryos can adapt to their abnormalities and persist in development, resulting in positive IVF outcomes.

Eric Simpson, M.D. is quoted in an article about clinical trial results for the drug bermekimab to treat patients with atopic dermatitis.

Esther Choo, M.D., M.P.H. speaks about her experience and research in gender equity and harassment.

OHSU School of Dentistry researchers create a filling made from the additive thiourethane, which is included in the protective coatings for cars and decks. According to Carmen Pfeifer, D.D.S, Ph.D., this material makes dental fillings two times more resistant to breakage than standard fillings.